For a patient experiencing a severe ischemic stroke, the standard of care is clear. A neurointerventionalist must thread a catheter through an artery to the brain and physically remove the clot, a procedure known as a mechanical thrombectomy. The clinical evidence is unambiguous. It saves lives and preserves function. Yet the company Remedy Robotics cites a brutal statistic: fewer than 3% of eligible patients worldwide can access this life-saving intervention in time [Remedy Robotics, retrieved 2026]. The limiting factor is not the procedure, but the profound geographic scarcity of the specialists who can perform it.
This is the clinical chasm that Remedy Robotics, a San Francisco-based healthtech company founded in 2020, is attempting to bridge with robotics and AI. Its core product, the N1 System, is an AI-enabled robotic platform designed for neurovascular, coronary, and peripheral vascular procedures. The immediate ambition is not full autonomy, but remote operation. It aims to let a specialist seated at a console hundreds of miles away control robotic catheters inside a patient at a local hospital. In October 2025, the company reported completing the world's first remote neurointerventional procedures using the N1 System at St. Michael's Hospital in Toronto, with surgeons controlling the system from a separate location [Remedy Robotics, October 2025]. That milestone, while early, provided a crucial proof of concept for the company's central thesis.
The Clinical Wedge: From Remote Control to Regulatory Pathway
The company's strategy follows a familiar but high-stakes playbook in medical devices. First, demonstrate that a robot can safely replicate a human specialist's actions under direct teleoperation. Then, layer on AI-assisted automation for specific, repetitive sub-tasks within the procedure. The long-term vision hinted at in company materials includes greater autonomy, but the near-term regulatory and commercial path runs through remote telepresence [Remedy Robotics, retrieved 2026]. The recent $62 million Series B round, led by DCVC and closed in November 2026, is explicitly earmarked to advance this path [PR Newswire, November 2026].
According to the company, the proceeds will support a planned pivotal clinical trial and work toward FDA approval for the N1 System [Securities.io, November 2026]. This capital infusion shifts the company from a prototyping and early-demonstration phase into the rigorous, expensive world of pivotal trials. Success here would not just validate the technology. It would begin to redefine where specialized stroke care can be delivered, potentially turning any hospital with an emergency room and the robotic system into a thrombectomy-capable center.
The Team Building the Surgeon's Extended Hand
The founders bring a blend of clinical perspective and deep technical robotics expertise, a necessary fusion for a venture of this complexity. Dr. David Bell, the co-founder and CEO, is described as a Perth-born doctor who leads the company's commercial and clinical programs [Startup Daily, retrieved 2026]. His co-founder and CTO, Jake Sganga, is a Stanford-trained robotics expert who leads hardware, software, and machine-learning work [Finsmes, November 2026]. Sganga's PhD research at Stanford focused on using sensor data to control flexible surgical devices in real time, a foundational skill for this endeavor [Stanford Bio-X, retrieved 2026].
The team remains lean, with approximately 20 employees as of July 2026 [LeadIQ, July 2026]. Current job listings point to a scaling focus on the hard disciplines required for a regulated medical device: roles for a Head of Regulatory Affairs, a Quality Engineer, and multiple Autonomy and DevOps Engineers are actively posted [Remedy Robotics, November 2026].
| Role | Name | Focus |
|---|---|---|
| Co-Founder & CEO | Dr. David Bell | Commercial & Clinical Strategy |
| Co-Founder & CTO | Jake Sganga | Hardware, Software, & Autonomy |
| Chief Commercial Officer | Ben Murphy | Partnerships & Commercialization [Ben Murphy - LinkedIn, retrieved 2026] |
Traction and the 100-Hospital Network
For a pre-FDA approval device, Remedy Robotics's claimed commercial footprint is notable. The company states it collaborates with more than 100 hospitals worldwide [HIT Consultant, November 2026]. This network is likely crucial for its clinical trial strategy and for building the procedural datasets needed to train its AI models. These collaborations are not yet revenue-generating product sales, but they represent early clinical buy-in and access to the environments where the N1 System must eventually prove itself. The investor syndicate, which includes UC Investments, Skip Capital, and Tony Fadell's Build Collective alongside lead DCVC, suggests confidence in both the technical and clinical roadmap [PR Newswire, November 2026].
2026 Series B | 62 | M USD
The Daunting Road to Standard of Care
The ambition is vast, and so are the hurdles. The risks for Remedy Robotics are not subtle. They are the fundamental challenges of introducing a complex new hardware-and-software system into one of medicine's most time-sensitive and high-risk procedures.
- Regulatory gravity. The path to FDA approval for a Class II or III device intended for remote stroke surgery is long, expensive, and uncertain. The $62 million Series B is a substantial war chest, but pivotal trials in this space routinely cost nine figures. Any significant clinical setback or regulatory delay could necessitate another major financing round under difficult conditions.
- Clinical adoption friction. Even with approval, changing hospital workflows and convincing neurointerventionalists to trust a robotic platform for emergent cases is a profound behavioral challenge. The system must not just be as good as a human. It must be seamlessly better within the chaotic context of a stroke alert.
- The autonomy question. The leap from teleoperation to meaningful AI autonomy is a research frontier, not an engineering sprint. Over-promising on autonomy could distract from the already monumental task of perfecting and deploying the remote telepresence model.
The company's most plausible answer to these risks is focus. By concentrating on the specific, high-value problem of stroke thrombectomy, it avoids the trap of being a general-purpose robot in search of a procedure. Its reported hospital network provides a foundation for trial recruitment and real-world feedback. And its funding positions it to tackle the next concrete milestone: generating the clinical data the FDA will require.
The Next Twelve Months and the Patient in the Room
For Remedy Robotics, the coming year is about translating a dramatic technical demonstration into a structured regulatory submission. The planned pivotal trial at a University of California facility will be the central event [PR Newswire, November 2026]. Success will be measured not in peer-reviewed publications alone, but in the clarity of the data pathway toward a de novo request or PMA supplement with the FDA.
The patient population here is specific: adults suffering acute ischemic stroke due to large vessel occlusion, for whom every minute of delay means the loss of nearly two million neurons. Today, the standard of care for these patients is a tragic geographic lottery. If they present to a comprehensive stroke center with a neurointerventionalist on call, they have a chance. If they do not, they face disability or death. Remedy Robotics is betting that a robotic system, guided remotely by a specialist, can break that lottery. The $62 million is a vote of confidence that the bet is worth making, but the real verdict will be written in clinical endpoints and, eventually, in the preserved abilities of patients far from any major medical center.
Sources
- [PR Newswire, November 2026] Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhere | https://www.prnewswire.com/news-releases/remedy-robotics-raises-62-million-series-b-to-bring-life-saving-cardiovascular-intervention-to-patients-everywhere-302939871.html
- [Finsmes, November 2026] Remedy Robotics Raises $62M in Series B Funding | https://www.finsmes.com/2026/11/remedy-robotics-raises-62m-in-series-b-funding.html
- [HIT Consultant, November 2026] Remedy Robotics Raises $62 Million Series B | https://hitconsultant.net/2026/11/16/remedy-robotics-raises-62-million-series-b-dcvc-endovascular-stroke-robotics/
- [Remedy Robotics, retrieved 2026] Remedy Robotics | AI-powered endovascular intervention | https://www.remedyrobotics.com/
- [Remedy Robotics, October 2025] Remedy Robotics completes world's first remote neurointerventional procedures | https://www.remedyrobotics.com/
- [Securities.io, November 2026] Remedy Robotics Raises $62M Series B Led by DCVC | https://www.securities.io/
- [Startup Daily, retrieved 2026] Expats remote surgery medtech scores $92 million Series B for stroke care | https://www.startupdaily.net/topic/funding/expats-remote-surgery-medtech-scores-92-million-series-b-for-stroke-care/
- [LeadIQ, July 2026] Remedy Robotics employee count | https://leadiq.com/
- [Ben Murphy - LinkedIn, retrieved 2026] Ben Murphy profile | https://www.linkedin.com/
- [Stanford Bio-X, retrieved 2026] Jake Sganga PhD research description | https://biox.stanford.edu/
- [Overnight Success, October 2025] Remote surgery in Toronto | https://www.overnightsuccess.com/